glp 1 agonists mechanism of action Frontiers GLP-1 and Anesthesia: Considerations and
Description
Months 6 to 12 and beyond: maximum results and maintenance The STEP trials showed that semaglutide 2.4 mg produces an average of approximately 15% body weight loss by week 68, roughly 16 months
But this testing used the mammalian, not the fish form
E.GagginH
AbbVie is investing in the development of novel GLP-1-based compounds and combination therapies to enhance weight loss efficacy
10.1016/j.bbrc.2015.08.092 145 WangA.LiT.AnP.YanW.ZhengH.WangB.et al (2017)
Further data are needed to understand if the reduction in CV outcomes with empagliflozin is a class effect
